BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xechem International (XKEM) Announces Delay in Quarterly Filing


8/20/2007 1:15:38 PM

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International (OTC BB: XKEM) announced today that it has delayed the filing of its Form 10-Q for the quarter ended June 30, 2007. In addition, Dr. Robert Swift, the interim chief operating officer has assumed the position of Chief Oversight Officer, in lieu of the former position, vested with the authority to act on behalf of the Company, pending appointment of a full time chief executive officer. According to, Dr. Swift, “Due to recent changes in personnel at the Company, it is imperative that current management obtain additional financial information before it is prepared to issue financial statements to the public. We are aware of the obligation of the Company to make timely filings of its financial statements both pursuant to its public registration and the loan covenants with respect to the recent convertible debenture issuances (as summarized in prior 8-K filings and which require timely filing of such reports), however, management is not prepared to release financial statements at this time. The Company continues its initiatives to increase productivity at its Xechem Pharmaceuticals Nigeria facility.”

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES